Amneal Faces Slower Revenue Outlook as Analysts Flag ROIC Concerns for AMRX

Amneal Pharmaceuticals (AMRX) traded at $12.64 as of May 14, 2026, with shares up 6.2% over the past six months, trailing the S&P 500’s 7.9% gain, according to a StockStory analysis that cited slowing growth and weak capital returns as key risks. Sell-side analysts expect Amneal’s revenue to rise 2.4% in the 12 months through May 14, 2027, down from an 8.7% annualized growth rate over the past five years. The report said the deceleration points to potential demand headwinds for the company’s products and services. StockStory also cited Amneal’s five-year average return on invested capital of 4.9%, below the typical cost of capital for health care companies. The stock trades at 13.3 times forward earnings, a valuation the report called reasonable but not compelling versus other investment opportunities.